Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Comparison of diabetic nephropathy between male and female eNOS-/- db/db mice.

Ma Y, Li W, Yazdizadeh Shotorbani P, Dubansky BH, Huang L, Chaudhari S, Wu P, Wang LA, Ryou MG, Zhou Z, Ma R.

Am J Physiol Renal Physiol. 2019 May 1;316(5):F889-F897. doi: 10.1152/ajprenal.00023.2019. Epub 2019 Feb 27.

PMID:
30810354
2.

Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice.

Zhao HJ, Wang S, Cheng H, Zhang MZ, Takahashi T, Fogo AB, Breyer MD, Harris RC.

J Am Soc Nephrol. 2006 Oct;17(10):2664-9. Epub 2006 Sep 13.

3.

Role of endothelial nitric oxide synthase in diabetic nephropathy: lessons from diabetic eNOS knockout mice.

Takahashi T, Harris RC.

J Diabetes Res. 2014;2014:590541. doi: 10.1155/2014/590541. Epub 2014 Oct 13. Review.

4.

Deficiency of endothelial nitric-oxide synthase confers susceptibility to diabetic nephropathy in nephropathy-resistant inbred mice.

Kanetsuna Y, Takahashi K, Nagata M, Gannon MA, Breyer MD, Harris RC, Takahashi T.

Am J Pathol. 2007 May;170(5):1473-84.

5.

Low nitric oxide bioavailability upregulates renal heparin binding EGF-like growth factor expression.

Miyazawa T, Zeng F, Wang S, Fan X, Cheng H, Yang H, Bian A, Fogo AB, Harris RC.

Kidney Int. 2013 Dec;84(6):1176-88. doi: 10.1038/ki.2013.214. Epub 2013 Jun 12.

6.

Arginase inhibition mediates renal tissue protection in diabetic nephropathy by a nitric oxide synthase 3-dependent mechanism.

You H, Gao T, Cooper TK, Morris SM Jr, Awad AS.

Kidney Int. 2013 Dec;84(6):1189-97. doi: 10.1038/ki.2013.215. Epub 2013 Jun 12.

7.

Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy.

Nakagawa T, Sato W, Glushakova O, Heinig M, Clarke T, Campbell-Thompson M, Yuzawa Y, Atkinson MA, Johnson RJ, Croker B.

J Am Soc Nephrol. 2007 Feb;18(2):539-50. Epub 2007 Jan 3.

8.

Role of MKK3-p38 MAPK signalling in the development of type 2 diabetes and renal injury in obese db/db mice.

Lim AK, Nikolic-Paterson DJ, Ma FY, Ozols E, Thomas MC, Flavell RA, Davis RJ, Tesch GH.

Diabetologia. 2009 Feb;52(2):347-58. doi: 10.1007/s00125-008-1215-5. Epub 2008 Dec 9.

PMID:
19066844
9.

p27(Kip1) Knockout mice are protected from diabetic nephropathy: evidence for p27(Kip1) haplotype insufficiency.

Wolf G, Schanze A, Stahl RA, Shankland SJ, Amann K.

Kidney Int. 2005 Oct;68(4):1583-9.

10.

Improvement of endothelial nitric oxide synthase activity retards the progression of diabetic nephropathy in db/db mice.

Cheng H, Wang H, Fan X, Paueksakon P, Harris RC.

Kidney Int. 2012 Dec;82(11):1176-83. doi: 10.1038/ki.2012.248. Epub 2012 Jul 11.

11.

Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury.

Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH.

Kidney Int. 2004 Jan;65(1):116-28.

12.

Diabetic eNOS knockout mice develop distinct macro- and microvascular complications.

Mohan S, Reddick RL, Musi N, Horn DA, Yan B, Prihoda TJ, Natarajan M, Abboud-Werner SL.

Lab Invest. 2008 May;88(5):515-28. doi: 10.1038/labinvest.2008.23. Epub 2008 Apr 7.

13.

Chronic diabetic nephropathy: role of inducible nitric oxide synthase.

Trachtman H, Futterweit S, Pine E, Mann J, Valderrama E.

Pediatr Nephrol. 2002 Jan;17(1):20-9.

PMID:
11793130
14.

Vascular endothelial growth factor-receptor 1 inhibition aggravates diabetic nephropathy through eNOS signaling pathway in db/db mice.

Yang KS, Lim JH, Kim TW, Kim MY, Kim Y, Chung S, Shin SJ, Choi BS, Kim HW, Kim YS, Chang YS, Kim HW, Park CW.

PLoS One. 2014 Apr 23;9(4):e94540. doi: 10.1371/journal.pone.0094540. eCollection 2014.

15.

eNOS deficiency predisposes podocytes to injury in diabetes.

Yuen DA, Stead BE, Zhang Y, White KE, Kabir MG, Thai K, Advani SL, Connelly KA, Takano T, Zhu L, Cox AJ, Kelly DJ, Gibson IW, Takahashi T, Harris RC, Advani A.

J Am Soc Nephrol. 2012 Nov;23(11):1810-23. doi: 10.1681/ASN.2011121170. Epub 2012 Sep 20.

16.

Role of blood pressure and the renin-angiotensin system in development of diabetic nephropathy (DN) in eNOS-/- db/db mice.

Zhang MZ, Wang S, Yang S, Yang H, Fan X, Takahashi T, Harris RC.

Am J Physiol Renal Physiol. 2012 Feb 15;302(4):F433-8. doi: 10.1152/ajprenal.00292.2011. Epub 2011 Nov 23.

17.

Fluorofenidone attenuates diabetic nephropathy and kidney fibrosis in db/db mice.

Wang LH, Liu JS, Ning WB, Yuan QJ, Zhang FF, Peng ZZ, Lu MM, Luo RN, Fu X, Hu GY, Wang ZH, Tao LJ.

Pharmacology. 2011;88(1-2):88-99. doi: 10.1159/000329419. Epub 2011 Aug 16.

PMID:
21847000
18.

A modest decrease in endothelial NOS in mice comparable to that associated with human NOS3 variants exacerbates diabetic nephropathy.

Wang CH, Li F, Hiller S, Kim HS, Maeda N, Smithies O, Takahashi N.

Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):2070-5. doi: 10.1073/pnas.1018766108. Epub 2011 Jan 18. Erratum in: Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3453.

19.

Nicorandil as a novel therapy for advanced diabetic nephropathy in the eNOS-deficient mouse.

Tanabe K, Lanaspa MA, Kitagawa W, Rivard CJ, Miyazaki M, Klawitter J, Schreiner GF, Saleem MA, Mathieson PW, Makino H, Johnson RJ, Nakagawa T.

Am J Physiol Renal Physiol. 2012 May 1;302(9):F1151-60. doi: 10.1152/ajprenal.00596.2011. Epub 2012 Feb 15.

20.

Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody.

Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, Schrijvers BF, Tilton RG, Rasch R.

Diabetes. 2002 Oct;51(10):3090-4.

Supplemental Content

Support Center